INTRODUCTION
One of the major advances in studying protein function in the last few years has been the use of RNAi technology to target the knockdown of specific mRNAs 1, 2 . However, this technology has several limitations. For example, one restriction has been that this procedure has been used largely to target the removal of mRNA encoding a single protein. Several laboratories, including ours, have recently developed procedures for simultaneous targeted removal of two or more genes in various organisms, thereby expanding the usefulness of RNAi technology as a tool for studying protein function. These advances have been made through the development of vectors that allow the insertion of multiple shRNA encoding sequences [3] [4] [5] [6] [7] [8] [9] [10] ; these vectors have been used to simultaneously target a variety of genes 3, 4, [6] [7] [8] . As efficient knockdown of some mRNAs has been difficult to achieve, several of the shRNA vectors have also been used to target multiple sites within a single mRNA to maximize knockdown efficiency 3, [5] [6] [7] 9, 10 . Thus, these shRNA vectors have been used to target either multiple genes or multiple sites within one gene in a number of organisms, including mammals 3, 6, 7 . Although vectors similar to the one we have developed have also been used in mammals by other investigators [3] [4] [5] [6] [7] 9, 10 , our vector has the advantage that it has been specifically designed to facilitate the repeated insertion of multiple shRNA cassettes 3 . Furthermore, the strategy described in this protocol can be used to modify other vectors with different promoters (e.g., H1 or 7SK, and so on.); and by making the restriction enzyme sites of these promoter-shRNA cassettes from different vectors compatible with each other, efficient combination of multiple cassettes with different promoters can be achieved.
Another important constraint in RNAi technology has been that it was designed to study only the effects of the loss of the targeted protein, precluding a comprehensive analysis of overall protein function. Several gene replacement strategies for restoring protein expression have been developed in mammalian and numerous other systems that circumvent the RNAi knockdown vector. These strategies include the use of silent mutations (i.e., degenerative codon nucleotides) in the knock-in vector that bypass the targeting vector [11] [12] [13] [14] [15] , species variations in the shRNA targeted region between the host gene and the knock-in homologous genes 11, 16 , simultaneous microinjection of knockdown or knock-in RNAs into Xenopus oocytes 15 and other similar strategies. One strategy, termed 'differential RNA interference' , involves targeting the 3¢-untranslated region (3¢-UTR) of wild-type mRNA with the simultaneous expression of a vector containing only the coding region of the targeted gene 17 . We previously used a similar strategy for studying the function of selenium-containing proteins (selenoproteins) by targeting the 3¢-UTR 18 that contains the essential selenocysteine insertion sequence (SECIS) element, which dictates selenocysteine insertion in response to the UGA termination codon 19 . As the SECIS element is required for the translation of selenoprotein mRNA, shRNAs were designed to target other regions within the 3¢-UTR and mutations were made in the knock-in vector to circumvent shRNA targeting, rather than deleting the entire 3¢-UTR 18 .
All of the above gene replacement strategies are based on modification of the shRNA-targeted region to efficiently re-express recombinant genes. The most commonly used strategy involves generating silent mutations in the coding regions [11] [12] [13] [14] [15] . However, a limitation of this method is that silent mutations may affect the expression of the recombinant genes 20 . Knock-in of homologous genes 11, 16 is an alternative method to bypass shRNA targeting, though it is limited by the availability of such genes. In addition, some homologous genes may not have an identical function to the shRNA-targeted gene(s) 11 . Targeting the 3¢-UTR has been shown to be as effective as targeting the coding region 21, 22 , and should work on any gene provided the targeted gene contains a suitable target region. This method provides greater flexibility in re-expressing the recombinant genes.
This protocol describes the design and modification of novel shRNA vectors for the knockdown of multiple genes, permits testing of the knockdown efficiency of each shRNA and allows for easier combination of the most efficient promoter-shRNA cassettes from different genes without constructing additional shRNA vectors. In addition, the strategy for re-expressing one or more recombinant genes has been introduced for the purpose of either confirming the on-targeting effects (i.e., that the observed phenotypes are the result of shRNA-induced effects on the targeted gene and not because of the effects on non-targeted genes) of the shRNA knockdown or analyzing the function of modified recombinant genes.
Overview of the procedure
To facilitate the use of our protocol, an overview of the entire procedure is shown in Figure 1 . Construction of the vectors used in the protocol is discussed below. For stable and simultaneous knockdown of multiple genes, it is highly recommended to insert all of the shRNAs into a single vector for easier transfection of cells. An shRNA vector must be designed and constructed to allow for easier and repetitive insertion of multiple shRNAs. In this protocol, a U6 promoter-containing vector (pSilencer 2.1 U6 Hygro) is modified for this purpose. After selecting an shRNA target region and synthesizing oligonucleotides, each shRNA is cloned into this modified vector individually to add the U6 promoter. After digestion of the cloned shRNA and isolation of the resulting U6-shRNA cassette, cassettes can then be inserted in tandem. Either stable transfection or transient transfection can be used to evaluate knockdown efficiency and off-targeting effects of each individual shRNA before combining multiple shRNAs into a single vector. The advantage of using transient transfection to monitor knockdown efficiency is that it requires only 2-3 d to determine efficiency, whereas stable transfection may take 3-4 weeks. However, the efficiency of transient transfection can vary from cell type-to-cell type and cannot be used with every cell line to assess whether knockdown has occurred, in which case stable transfection would be required to be conclusive. If two or more effective shRNAs from one gene generate the same phenotype, this result can be considered an on-targeting effect. If the shRNA targeted sequences are available in a public siRNA database (e.g., http://www.rnainterference. org), or have been previously identified and characterized, these evaluation steps may be omitted. After evaluating the knockdown effects of each shRNA, the most effective shRNAs from each gene can be combined for targeting multiple genes simultaneously. Finally, after generating a stable cell line with multiple shRNAs and confirming the knockdown efficiency of each gene, the cell line can be transfected with the gene-replacement vector, containing the modified target gene that it no longer contains target sites for the shRNAs.
Advantages and limitations of the method Generating a construct containing multiple shRNAs for targeting the simultaneous knockdown of more than one gene expands the powerful tool of RNAi technology. This multiple shRNA knockdown procedure makes available a rapid, simple and efficient means of producing stably transfected, multiple knockdown shRNA cell lines. In addition, it allows us to target multiple genes to clarify their cellular role and their possible interplay that may advance our approaches in therapeutic strategies. It should also be noted that the multiple shRNA targeting vector may be used to knockdown multiple sites within a single gene if no one site may sufficiently remove protein expression. Alternatively, the multiple shRNA targeting vector can be used to target multiple sites within a single mRNA in the event no one site may effectively knockdown protein expression.
When an investigator wishes to overexpress a specific gene by introducing the corresponding recombinant gene, the interpretation of the resulting overexpression is often hampered by the interference of endogenous mRNA expression. Unless cell lines from naturally occurring mutations or knockout mice are available that remove expression of the endogenous gene, it otherwise may be difficult and time-consuming to remove endogenous gene expression. Multiple shRNAs can be used to selectively suppress endogenous gene expression without affecting the expression of a transfected, recombinant version of the same protein. Since gene expression may be restored either individually or collectively, we now have another means of elucidating the interplay of different proteins including their individual or collective consequences on overall cell function [11] [12] [13] [14] [15] 18, 23 . The recovery of gene function by re-expression of the recombinant gene(s) can also be used as a means of excluding possible off-targeting effects of the shRNA knockdown 11, 16 .
One limitation of shRNA technology is that it can be difficult to completely knockdown the expression of a gene. In most cases, a low expression level of targeted endogenous genes remains, and this low level of expression may still be adequate for gene function affecting the interpretation of re-expression of the corresponding recombinant gene. In such cases, it may be necessary to generate a cell line from knockout mice in order to study the function of the gene under investigation. Experimental design Choice of promoter for the shRNA vector. In this protocol, we elected to use the pSilencer 2.1 U6 Hygro vector as the backbone to generate a multiple shRNA vector. The U6 and H1 promoters are commonly used for expressing shRNA since they have a well defined start and stop signal with all required regulatory elements located immediately upstream of the transcripted sequence, which makes it easy to manipulate for direct expression of shRNA 24, 25 . The U6 vector is used herein since it has been shown to be more efficient than the H1 promoter in expressing shRNA 26, 27 . The efficiency of the 7SK promoter is comparable to the efficiency of U6 promoters [28] [29] [30] . Other RNA Polymerase III promoters, such as 5S, 7L and tRNA promoters, have also been used to drive shRNAs 24, 25, 31, 32 . It should be noted that the highly expressed U6 promoter may cause greater cell toxicity than other promoters 26, 33 , whereas shRNA vectors with a different promoter, such as H1 and tRNA promoters, may cause less toxicity and can be used as alternatives 25, 26, 31 . However, as the control cells are also transfected with the same vector, toxicity due to the vector should be similar between control and targeted cells. In the event a vector with a different promoter is employed, the restriction enzyme sites used for modification and cloning will be different and appropriate changes to accommodate these restriction sites will be necessary. For transfection of primary cells or other difficult-to-transfect cells, a lentiviral or a retroviral vector can be used. In this case, each shRNA should be driven by different promoters (e.g., U6, H1, 7SK, 5S, 7L or tRNA promoters) 7, 10, 24, 25, 31, 32 to avoid deletions of shRNA cassettes due to recombination of repeat promoter sequences during transduction of the viral vector 34 . The number of shRNAs that can be combined in one vector will be limited by the number of promoters available.
Modification of shRNA vectors to enable cloning of multiple shRNAs. The EcoR I sites at position 4,110 in the pSilencer 2.1 U6 Hygro vector should initially be removed to generate a single EcoR I site immediately upstream of the U6 promoter (see Fig. 2a , an annealed shRNA dsDNA fragment, designated shRNA1, is then cloned into pU6-m4 at the BamH I and Hind III sites to produce the pU6-shRNA1 vector and a second annealed shRNA dsDNA fragment, designated shRNA2, is cloned separately into pU6-m4 at the BamH I/Hind III sites to produce a second pU6-shRNA vector designated pU6-shRNA2. Other annealed shRNA dsDNA fragments (e.g., shRNA3, shRNA4, and so on) can also be cloned in the same manner. In Stage 4A, one of the pU6-shRNA constructs, e.g., U6-shRNA1, is selected as the backbone for adding additional shRNA cassettes and is digested with Mfe I/Xho I. In Stage 4B, one of the separately prepared U6-shRNA vectors is digested with EcoR I/Xho I to yield a 400 bp, shRNA fragment (designated U6-shRNA2) with an EcoR I site at the U6 promoter 5¢ end and a Xho I site at the 3¢ end, which is cloned into the Mfe I and Xho I sites of the pU6-shRNA1 construct (Stage 5) to generate the 5.3 kb pU6-shRNA1/ shRNA2 construct. As noted in the text, additional shRNA units can then be individually added to the pU6-shRNA using the same strategy. In (b), the sequences of the Mfe I and EcoR I sites are given showing that they have compatible cohesive ends, but after ligation, the newly generated site cannot be re-cut by either endonuclease.
changing the EcoR I site at position 4,110 are shown in Table 1 , wherein the red letters represent the EcoR I site to be mutated. Then, Mfe I and Xho I sites can be added downstream of the U6 shRNA cassette at positions 384 and 393, respectively, as shown in Figure 2a , Stage 2. The primers (Mfe-Xho-Mut-F and Mfe-XhoMut-R) used for mutagenesis are also shown in Table 1 (the red letters represent the enzyme sites to be added).
Mfe I and EcoR I have matched ends, which can be ligated to each other, but cannot be re-cut by either endonuclease after ligation (Fig. 2b) . This feature facilitates the repetitive insertion of multiple U6-shRNA cassettes into vector 3. The modified U6 vector described above (designated as pU6-m4 which is available upon request) is used for generating multiple shRNA constructs. Each shRNA oligonucleotide lacking a U6 promoter (see Fig. 3a ) can be individually cloned into this modified vector that contains the U6 promoter using the BamH I/Hind III sites (Fig. 2a, Stage 3 ) generating a variety of constructs, each containing different shRNAs (designated shRNA1 and shRNA2 in the figure). One of the constructs (designated pU6-shRNA1) is selected as the backbone for adding additional U6-shRNAs and it can then be cut with Mfe I/Xho I restriction enzymes (designated Stage 4A). Another U6-shRNA construct (designated U6-shRNA2) is cut with EcoR I/ Xho I to generate a U6-shRNA cassette (designated U6-shRNA2, Stage 4B) which in turn can be inserted into Mfe I/EcoR I sites (Stage 5) to yield the pU6-shRNA1/shRNA2 construct. The latter construct is then used to insert additional U6-shRNA cassettes by repeating stages 4A, 4B and 5.
The above strategy for modifying vectors and inserting shRNAs can also be used to modify vectors with different shRNA promoters (e.g., U6, H1, 7SK, 5S, 7L and tRNA promoters). Each shRNA can be inserted into one of the modified vectors separately, and then, the different shRNA cassettes with different promoters will possess compatible restriction enzyme sites (e.g., EcoR I/Mfe I) and can easily be combined in one vector. This alternative cloning strategy is very useful when viral vectors are used (see 'Choice of promoter for the shRNA vector').
shRNA design. The strategy for choosing shRNA target sites is based on previously published observations 35, 36 . Selecting 21-23 nt sequences in the target mRNA that begin with an AA dinucleotide (the targeted sequences, 19-21 nt, start right after the AA dinucleotide) as the targeted region will be ideal though sequences with other dinucleotides will work as well. The GC content of the targeted regions should be between 30-50% for proper shRNA functionality 36 . A nucleotide BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) of the chosen shRNA sequences should be carried out to minimize the possibility of shRNA off-targeting effects.
There are alternative programs for choosing shRNA targeting sequences 3, 11, 18, 37 , for example, 'siDESIGN' from Dharmacon Research (Chicago, Illinois, USA), 'BLOCK-iT RNAi Designer' from Invitrogen, 'siRNA Target Finder' from Ambion or other similar programs. Some of the above programs, like 'siDESIGN' of Dharmacon, can also help to select shRNA with an optimal seed region 38, 39 to reduce unwanted cellular effects and avoid antisense strand-mediated off-targeting effects (see below for further control of off-targeting).
Forward and reverse chains of oligonucleotides containing 19-21 nucleotides of sense and 19-21 nucleotides of antisense targeting sequences with an intervening TTCAAGAGA spacer should be synthesized. This spacer sequence is used in the original pSilencer 2.1 U6 Hygro vector, which aids the transcribed shRNA in forming a hairpin structure. A model pair of oligonucleotide sequences, designated shRNA-F and shRNA-R, is shown in Table 1 , where 'X' represents the sense (shown in blue) and anti-sense (shown in red) targeting sequences of the shRNA. Several extra nucleotides (shown in green) should be added to generate BamH I and Hind III restriction enzyme sites on the annealed dsDNA fragment (see Table 1 ). The forward and reverse chains of oligonucleotides are annealed to form a dsDNA fragment with BamH I and Hind III sites for inserting into pU6-m4 (see Fig. 3a ). The transcribed shRNA will form a hairpin structure with an intervening ttcaagaga loop as shown in Figure 3b . Four to five shRNA target sequences should be chosen and the corresponding annealed dsDNA fragments can be cloned into the modified U6 vector, pU6-m4, as described above and in Steps 9-18 below.
Controlling for off-target effects and cell toxicity. To evaluate off-targeting effects 40 , two different combinations of effective shRNAs from each gene can be tested separately (see ANTICIPATED RESULTS for detail). As off-targeting is sequence dependent, then, if vectors with different U6-shRNA combinations from the same genes show the same phenotype after transfection, the possibility that the observed phenotype is a result of offtargeting is substantially reduced. If different phenotypes are observed with different shRNAs targeting the same gene, and reduction in the targeted mRNA is the same, this result is almost certainly because of off-targeting, and more shRNAs targeting different regions should be tested. Alternatively, knock-in of the modified gene to specifically recover the lost gene function provides strong evidence that observed phenotypes are not the result of offtargeting effects of the shRNA knockdown 11, 16 .
shRNA-induced cell toxicity is another potential issue that needs to be addressed 26, 33 . shRNA cell toxicity is thought to arise from oversaturation of the shRNA pathway 33 , although the precise mechanism is unknown. A control vector should always be included to evaluate shRNA toxicity and to analyze loss-of-gene function. If cells transfected with a control vector exhibit abnormal growth or death, it is likely due to U6 promoter toxicity. In this case, another promoter, such as H1 or a tRNA promoter, can be used.
Limits on the number of shRNAs that can be inserted. Clearly, there is a maximal number of shRNAs that can be inserted into one vector, as the vectors have a tendency to lose inserted large fragments (more than 10-15 kb) during cloning. As the U6-shRNA cascade is about 410 bp, a combination of 20 inserts should not pose a problem in cloning. We have successfully combined up to six different shRNAs from two different genes into one vector using our protocol, and efficiently knocked down both genes 3 .
Choice of cell line. Depending on the targeted genes, commonly used cell lines such as NIH 3T3 3, 11, 18 , HEK 293 7, 21 and HeLa cells 4,9,10 can be chosen. Cell lines can be pre-selected to check the expression level of the targeted gene(s) by northern and/or western blot analysis. Cell lines manifesting a higher expression level of the targeted gene(s) are generally better for investigating the knockdown effects. If stable transfection is used to knockdown gene expression, the efficiency of transfection will not be a concern in selecting the cell line(s), except in the case where a primary cell line is used in which case a viral vector will be required for introduction of the shRNA sequence(s) (see section 'Choice of promoter for the shRNA vector').
Several cell lines such as NIH 3T3, DT, TCMK and LLC-1 cells have been tested in our lab for the stable knockdown of various genes 3, 11, 18, 37, 41, 42 . The mRNA knockdown efficiencies caused by the corresponding shRNAs varied from 50% to 98%, as shown by northern blotting. The knockdown efficiency depends on the shRNA target sites (see ANTICIPATED RESULTS). Reduction in the expression of some genes due to the presence of the corresponding shRNA resulted in a dramatic effect on cell function, wherein the cells grew very poorly, with only 50% knockdown in mRNA levels (e.g., glutathione peroxidase 4 (GPx4)), whereas others reached B90% reduction in mRNA levels before manifesting a phenotypic change (e.g., SECp43). For most genes, the knockdown efficiency of an effective shRNA should reach 80-90% after stable transfection.
Generation of the expression vector for gene replacement(s).
To further examine the role(s) of targeted endogenous gene(s), other than assessing its (their) loss on cell function, an alternative strategy is required for replacing the knocked down gene(s), i.e., a gene replacement strategy, designed to circumvent the shRNA knockdown, is needed. The aim in this strategy is to introduce a cDNA construct of the targeted gene that has been modified so that it no longer contains target sites for the shRNAs, but still encodes a functional protein. This construct should restore full function and rescue any loss-of-function phenotype. Other modifications, such as changing key amino acids and adding or deleting domains, can also be made to the genes if those are desired for gene function analysis. In case the 3¢-UTR is targeted, the targeted region can either be deleted or individual bases mutated without affecting protein expression, or the coding region alone can be cloned into the expression vector 17, 18 . However, if the shRNA target region is located in the open reading frame, 4-5 mutations in the wobble positions of codons in the shRNA target region will need to be made [11] [12] [13] [14] [15] 23 . The modified gene expression vector can be transfected into the cells with shRNA knockdown of the endogenous gene(s). An example of mutating wobble bases at the 3¢ position is shown in Figure 3c .
Alternatively, after the above modifications have been completed, an entire gene expression cassette (including the promoter, the coding region and the polyA signal sequences) may also be inserted into the Xho I and Mfe I sites of the shRNA constructs. In this manner, the construct will contain both knockdown and knock-in cassettes, which will facilitate transfection and stabilization of gene expression in the cells. This will be especially helpful when the targeted genes are essential in which case the cells will not survive when the genes are knocked down. . pSilencer 2.1 U6 Hygro vector (Ambion, cat. no. AM5760) . pcDNA3.1 expression vector (Invitrogen, cat. no. V38520) . Oligos for mutagenesis of pSilencer 2.1 U6 Hygro-as listed in Table 1 (see also Experimental design) or user-defined if using a vector other than pSilencer 2.1 U6 Hygro (Sigma Genosys)
. shRNA oligos-user-defined for specific target genes (see Experimental design and Table 1) . Quick . Access to a darkroom equipped with film developer is needed for film autoradiography . Access to a PhosphorImager (GE Healthcare) instrument is needed for phosphor screen imaging REAGENT SETUP 50 mg ml À1 Ampicillin Prepare 50 mg ml À1 ampicillin, store at À20 1C up to 1 year. DMEM medium Add 10% FBS to DMEM medium, store at 4 1C up to 1 month. 1% Agarose gel Put 1 g of agarose powder in 98 ml H 2 O and melt the agarose in a boiling water bath, add 2 ml of 50Â TAE buffer and 10 ml of 10 mg ml À1 ethidium bromide, cool it down to about 60 1C and pour proper amount to the gel tanks. The cast agarose gels can be then left at room temperature (25 1C) up to 8 h before use.
PROCEDURE
Mutagenesis of pSilencer 2.1 U6 Hygro vector TIMING 1-2 weeks 1| Prepare the following reaction mix for one set of primers in a 0.2 ml thin-wall PCR tube using Ultra Pfu DNA polymerase. (Alternatively, a QuickChange site-directed mutagenesis kit may be purchased and the manufacturer's instructions followed): 3| After PCR, add 10 U of Dpn I into the PCR reaction tube and incubate at 37 1C for 1 h. The Dpn I will only digest and eliminate the plasmid template. ' PAUSE POINT Can be left overnight at 4 1C or stored frozen for up to 1 month at À20 1C.
4| Use 2 ml of Dpn I-treated DNA from Step 3 to transform GC5 high efficiency competent E. coli cells and plate on 50 mg ml À1 ampicillin LB plates following the manufacturer's instructions, and then incubate at 37 1C overnight.
5| Choose 2-3 colonies, and use each to individually inoculate 5 ml of LB broth supplemented with 100 mg ml À1 of ampicillin. Culture overnight at 37 1C in a shaking incubator at 250 rpm.
6| Next day, extract each plasmid using a Qiagen MiniPrep plasmid preparation kit (according to the manufacturer's instructions).
7| Sequence the plasmids using primer Rev2.0 (see Table 1 ) to confirm only the desired mutations that have been generated. m CRITICAL STEP The mutations should be confirmed by sequencing before proceeding to the next step.
8| Repeat Steps 1-7 to generate the other necessary mutations by using the plasmid generated in Step 7 as a template.
Generating single shRNA constructs TIMING 1-3 weeks 9| For each shRNA, set up the reaction tabulated below to anneal the corresponding forward and reverse shRNA oligonucleotides. Heat the mix to 95 1C for 5 min, and then let it cool slowly at room temperature (25 1C m CRITICAL STEP Do not use the MfeI and Xho I sites for inserting the shRNA targeting sequences. These two sites will be used to combine multiple shRNA cassettes into one vector.
11| Add 10 ml of 6Â DNA loading buffer and load onto a 1% (wt/vol) agarose gel with 1 mg ml À1 of ethidium bromide and run in 1Â TAE buffer at 100 V for about 30 min to allow the leading dye to reach two-third of the gel length. 12| Excise the band corresponding to the full-length vector (4.9 kb in the case of pU6-m4) under 360 nm UV light with a scalpel. Only one prominent band should be visible in the gel.
13| Use a Qiagen QIAquick Gel Extraction Kit to recover the digested plasmid from the gel and elute in 30 ml of elution buffer. Use 5 ml to measure the DNA concentration using a spectrophotometer. ' PAUSE POINT This purified fragment can be used immediately for ligation or can be stored at À20 1C up to 1 month.
14| Individually ligate each annealed oligonucleotide mix (from Step 9) into the modified shRNA vector digested with BamH I and Hind III (from Step 13) using a Quick Ligation kit: set up a separate reaction mix for each shRNA as tabulated below, and allow the ligation reaction to proceed at room temperature (25 1C) for 10 min. ' PAUSE POINT The ligation reactions can be used immediately for transformation or can be stored frozen for up to 1 week at À20 1C.
15| Use 2 ml of each ligation reaction from Step 14 to transform GC5 high efficiency competent E. coli cells and plate on 50 mg ml À1 ampicillin LB plates following the manufacturer's instructions, and then incubate at 37 1C overnight.
16| Choose 2-3 colonies for each ligation, and use them to individually inoculate 5 ml of LB broth supplemented with 100 mg ml À1 of ampicillin. Culture overnight at 37 1C in a shaking incubator at 250 rpm.
17| Extract each plasmid using a Qiagen MiniPrep plasmid preparation kit, according to the manufacturer's instructions.
18| Sequence the plasmids using primer Rev2.0 (see Table 1 ) to confirm that the generated shRNA vectors have the correct sequence. m CRITICAL STEP Confirm each shRNA sequence before proceeding to the next step.
Evaluating the knockdown efficiency of each shRNA TIMING 3-6 weeks 19| Culture NIH 3T3 cells in DMEM medium supplemented with 10% (vol/vol) FBS at 37 1C in a CO 2 incubator before transfection. If another cell line is selected for use, the appropriate culture medium and growth conditions should be used. m CRITICAL STEP A control vector, which has the similar nucleotide composition as the shRNA but lacks significant sequence homology to the genome, should always be included to evaluate shRNA toxicity and the effect of loss-of-gene function.
20| One day before transfection, plate 5Â10 5 cells in one well of a 6-well plate with 2 ml of growth medium without antibiotics so that cells are 90-95% confluent at the time of transfection. One well of cells is needed for each shRNA construct to be tested.
21| Transfect cells using Lipofectamine 2000 according to the manufacturer's instructions.
22| Incubate cells at 37 1C in a CO 2 incubator. Medium may be changed after 4-6 h.
23| Passage cells 1:5 into fresh growth medium 24 h after transfection at 37 1C in a CO 2 incubator. Optionally, 48-96 h after transfection, use 1Â10 6 of the cells to check the removal of targeted genes using northern blotting 43 and/or western blotting (http://www.e-biotek.com/protein/244-western-blot-protocol.html).
24| Add selective medium with hygromycin B (or appropriate antibiotic(s)) the next day. Treat cells with antibiotics for 2-3 weeks to stabilize the transfection at 37 1C in a CO 2 incubator. 1Â10 6 of the cells can be used to check the removal of targeted genes using northern 43 26| Add 10 ml of 6Â DNA loading buffer and load onto a 1% (wt/vol) agarose gel with 1 mg ml À1 of ethidium bromide and run in 1Â TAE buffer at 100 V for about 30 min to allow the leading dye to reach two-thirds of the gel length.
27| Excise the band corresponding to the 4.9 kb vector from Xho I and Mfe I digested reaction and the 400 bp U6-shRNA fragment from Xho I and EcoR I digested reaction under a 360 nm UV light with a scalpel. m CRITICAL STEP There should be only one 4.9 kb band visible in the gel for Xho I and Mfe I digested plasmid. Recover this band. The Xho I and EcoR I digested plasmid will show two bands (4.5 kb and 400 bp) in the gel. Be sure to recover the U6-shRNA band (400 bp) from the gel.
28| Use a Qiagen QIAquick gel extraction kit to recover the digested plasmid from the gel and elute in 30 ml of elution buffer. Use 5 ml to measure the DNA concentration using a spectrophotometer. ' PAUSE POINT These purified fragments can be used immediately for ligation or can be stored at À20 1C up to 1 month.
29| Ligate the purified vector and the shRNA insert (from Step 28) using a Quick Ligation kit, as tabulated below. Let the ligation reaction proceed at room temperature for 10 min. ' PAUSE POINT The ligation solution can be used immediately for transformation or can be stored frozen for up to 1 week at À20 1C.
30| Use 2 ml of ligated DNA from Step 29 to transform GC5 high efficiency competent E. coli and plate on 50 mg ml À1 ampicillin LB plates following the manufacturer's instructions, and then incubate at 37 1C overnight.
31| Choose 2-3 colonies, and use each to individually inoculate 5 ml of LB broth supplemented with 100 mg ml À1 of ampicillin. Grow overnight at 37 1C in a shaking incubator at 250 rpm.
32| Extract each plasmid using a Qiagen MiniPrep plasmid preparation kit (according to the manufacturer's instructions).
33| Sequence the plasmids using primer Rev2.0 (see Table 1 ) to confirm that the U6-shRNA fragments have been inserted into the correct position of vectors. m CRITICAL STEP Confirm each shRNA sequence before proceeding to the next step.
34| If more genes are to be targeted, repeat Steps 25-33 to combine more U6-shRNA cassettes into one vector. The plasmid created in Step 33 should be used as the 'vector' in subsequent cloning rounds. 
35|

ANTICIPATED RESULTS
The northern blot results of shRNA transfected NIH 3T3 cells are shown in Figure 4 . Figure 4a and b show the knockdown efficiency of each single shRNA targeting SECp43, which is involved in selenoprotein synthesis 3, 44 45, 46 . The range of knockdown efficiency varies from 40% to 98% depending on the targeting sites. The most efficient shRNA can be selected, e.g., lanes 1 or 5 for SECp43 (shSECp43-1 and shSECp43-5) and lanes 3 or 5 for PSTK (shPSTK-3 and shPSTK-5). Two different shRNA combinations of SECp43 and PSTK can be generated by joining shSECp43-1 and shPSTK-5, or shSECp43-5 and shPSTK-3. Figure 4c shows that SECp43 and PSTK were both simultaneously and efficiently removed using a shPSTK-3/shSECp43-5 double knockdown construct in which the two shRNAs are connected in tandem (lane 3). The selenoproteins, thioredoxin reductase 1 (TR1) and GPx1, were simultaneously targeted for removal by stably transfecting DT cells, which are k-ras expressing cells derived from NIH 3T3 cells 42 , with a shTR1 or shGPx1 double knockdown construct. The cells were then transiently transfected with either the knock-in construct that individually or simultaneously circumvented the targeting vector resulting in re-expression of one or both knocked down selenoproteins. All DT cells were labeled with 75 Se to monitor selenoprotein expression and the resulting labeled selenoproteins analyzed after electrophoresis of cell extracts (Fig. 5) . The expression of selenoproteins in cells stably transfected with the control vector, pU6, is shown in lane 1 of the figure. Both TR1 and GPx1 were effectively removed by the double targeting vector (lane 2). TR1 and GPx1 were not expressed upon replacement of TR1 and GPx1 wild-type genes due to the presence of the corresponding shRNAs that were generated from the stably transfected vector (Fig. 5, lanes 3 and 5) . However, by circumventing the targeting regions (i.e., defined as ki (knock-in) genes in the figure, see Fig. 5, lanes 4, 6 and 7) , these proteins were expressed in cells that were transiently transfected with vectors encoding TR1 and/or GPx1 genes with mutations in regions corresponding to the shRNAs.
